Metabolome Analysis of Esophageal Cancer Tissues Using Capillary Electrophoresis-time-of-flight Mass Spectrometry
Overview
Authors
Affiliations
Reports of the metabolomic characteristics of esophageal cancer are limited. In the present study, we thus conducted metabolome analysis of paired tumor tissues (Ts) and non-tumor esophageal tissues (NTs) using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). The Ts and surrounding NTs were surgically excised pair-wise from 35 patients with esophageal cancer. Following tissue homogenization and metabolite extraction, a total of 110 compounds were absolutely quantified by CE-TOFMS. We compared the concentrations of the metabolites between Ts and NTs, between pT1 or pT2 (pT1-2) and pT3 or pT4 (pT3-4) stage, and between node-negative (pN-) and node-positive (pN+) samples. Principal component analysis and hierarchical clustering analysis revealed clear metabolomic differences between Ts and NTs. Lactate and citrate levels in Ts were significantly higher (P=0.001) and lower (P<0.001), respectively, than those in NTs, which corroborated with the Warburg effect in Ts. The concentrations of most amino acids apart from glutamine were higher in Ts than in NTs, presumably due to hyperactive glutaminolysis in Ts. The concentrations of malic acid (P=0.015) and citric acid (P=0.008) were significantly lower in pT3-4 than in pT1-2, suggesting the downregulation of tricarboxylic acid (TCA) cycle activity in pT3-4. On the whole, in this study, we demonstrate significantly different metabolomic characteristics between tumor and non-tumor tissues and identified a novel set of metabolites that were strongly associated with the degree of tumor progression. A further understanding of cancer metabolomics may enable the selection of more appropriate treatment strategies, thereby contributing to individualized medicine.
Data-Driven Molecular Typing: A New Frontier in Esophageal Cancer Management.
Du Y, Gu B, Shi L, She Y, Zhao Q, Gao S Cancer Med. 2025; 14(5):e70730.
PMID: 40018789 PMC: 11868787. DOI: 10.1002/cam4.70730.
Nov P, Zheng C, Wang D, Sou S, Touch S, Kouy S Mol Med Rep. 2024; 30(6).
PMID: 39370813 PMC: 11450430. DOI: 10.3892/mmr.2024.13336.
Lin Z, Yang S, Qiu Q, Cui G, Zhang Y, Yao M Redox Biol. 2024; 75:103286.
PMID: 39079386 PMC: 11340627. DOI: 10.1016/j.redox.2024.103286.
The relationship and clinical significance of lactylation modification in digestive system tumors.
Wang G, Zou X, Chen Q, Nong W, Miao W, Luo H Cancer Cell Int. 2024; 24(1):246.
PMID: 39010066 PMC: 11251390. DOI: 10.1186/s12935-024-03429-8.
Balonov I, Mattis M, Jarmusch S, Koletzko B, Heinrich K, Neumann J J Cancer Res Clin Oncol. 2024; 150(7):331.
PMID: 38951269 PMC: 11217139. DOI: 10.1007/s00432-024-05857-5.